Outcomes Similar With Chemo Only Versus Chemoradiation for Gastric Adenocarcinoma
July 1st 2016Patients with stage Ib-IVa resectable gastric adenocarcinoma undergoing surgery with curative intent had similar survival outcomes regardless of whether they received chemotherapy or chemoradiotherapy after surgery.
Dr. Eileen O'Reilly on Factors to Consider in Pancreatic Cancer Treatment
June 30th 2016Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.
Daniel Sargent on International Collaboration for Colon Cancer Research
June 30th 2016Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.
QOL Sustained When Adding MM-398 to Standard Care in Pancreatic Cancer
June 30th 2016Adding MM-398 (irinotecan liposome injection; nal-IRI; Onivyde) to 5-fluorouracil and leucovorin had no negative effect on quality of life while significantly improving overall survival in patients with metastatic pancreatic cancer.
Dr. John Marshall on Differentiating Squamous and Adenocarcinoma in GI Cancers
June 30th 2016John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the difference between squamous and adenocarcinoma in esophageal and gastric cancer.
Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC
June 29th 2016Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.
Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC
July 16th 2015Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).
Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients
July 8th 2015Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.
Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma
July 7th 2015Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.
Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR
July 4th 2015The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.
Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC
July 4th 2015Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).
Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC
Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.
Dr. Eric Van Cutsem on Regorafenib for Metastatic Colorectal Cancer
July 3rd 2015Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
Hepatitis C "Revolution" May Transform Liver Cancer Outcomes
July 2nd 2015Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.
Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer
July 2nd 2015Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.
Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer
July 1st 2015Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).
Low BMI Prognostic for Worse Survival in Colorectal Cancer
July 1st 2015Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.